Turn Therapeutics (TTRX) executive compensation, 2026 proxy

Bradley Burnam, Chief Executive Officer, was paid $652,036 in 2025, up 52% from $429,320 the year before.

Filed
October 19, 2026
Annual meeting
November 30, 2026
Pay year
2025
Named executives
2
CEO total pay
$652,036+52% vs prior year
CEO target cash bonus
50% of base salaryUnder new employment agreement
CEO targeted equity grant
50% of base salaryBeginning with fiscal 2026
Interim CFO option awards
$1,244,1432025 grant-date fair value

How Burnam was paid

$652,036 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary71%Bonus29%

Named executive officers

ExecutiveTotal
Bradley BurnamChief Executive Officer$652,036
Zuraiz ChaudharyInterim Chief Financial Officer$1,426,754

What changed and why

  • $652K$652,036 CEO total compensation in 2025, up from $429,320 in 2024.
  • $186K$186,296 CEO bonus was reported for 2025; no CEO stock or option awards were reported.
  • $1.2M$1,244,143 in option awards accounted for the Interim CFO’s reported 2025 compensation.
  • 50%50% of base salary is the CEO’s target annual cash bonus and annual targeted equity grant value under the new agreement.
  • $585K$585,000 CEO base salary was approved in 2026, effective January 1, 2026.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.